Pyrimidine derivatives used as pi-3 kinase inhibitors

摘要

Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.